Tyra Biosciences, Inc. Total Liabilities
Tyra Biosciences, Inc. (TYRA) had Total Liabilities of $29.70 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-04
- 2026-06-30: Liabilities $29.70M.
- 2026-03-31: Liabilities $24.46M.
- 2025-12-31: Liabilities $23.43M.
- 2025-09-30: Liabilities $21.34M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $29.70M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $24.46M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $23.43M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $21.34M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $19.35M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $19.94M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $20.41M 10-K · filed 2026-03-02 |
| 2024-09-30 | $18.30M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $16.42M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $14.86M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $21.59M 10-K · filed 2025-03-27 |
| 2023-09-30 | $16.19M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $11.44M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $6.26M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $8.35M 10-K · filed 2024-03-19 |
| 2022-09-30 | $8.23M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $8.27M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $7.79M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $4.96M 10-K · filed 2023-03-22 |
| 2021-09-30 | $6.24M 10-Q · filed 2021-11-03 |
| 2020-12-31 | $2.00M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |